HEALTHMARKETWATCH
An experimental lung-cancer drug could replace Keytruda one day. But investors aren’t wowed.
An experimental lung-cancer drug, ivonescimab, showed a 34% reduction in risk of death compared to Keytruda. However, investors remain unimpressed by the results.
Related Signal
Adjacent reporting
- Akeso lung cancer drug shines in trials, boosting hopes in US$20b market
- Akeso lung cancer drug shines in trials, boosting hopes in US$20b market
- A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
- STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
- Chinese drug reduces lung cancer death risk by 34% in trial
- STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more